Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess whether chronic treatment with olanzapine
over a five-month period produces a significant increase in abnormalities in glucose levels.
The main secondary objective is to evaluate whether the increase in glucose levels and rate
of glucose abnormalities differs between Olanzapine and Risperidone during this treatment
period. Additional secondary objectives of the study are to investigate similar questions
with respect to glycohemoglobin, triglycerides and other measures of glucose and lipid
metabolism.
We hypothesize that Olanzapine will not be inferior to Risperidone in extent of increase in
the primary outcome measure of serum glucose, and secondary measures of glycohemoglobin,
insulin and lipids.